SCHEMBL981934

SCHEMBL981934

COc1cccc(-c2ccsc2C(=O)O)c1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.54
LMNA P02545 1/20 0.54
MAPT P10636 1/20 0.54
HSD17B10 Q99714 1/20 0.54
DHODH Q02127 1/20 0.54
HPGD P15428 1/20 0.52
RORB Q92753 3/20 0.50
RORC P51449 2/20 0.50
MEN1 O00255 1/20 0.50
KMT2A Q03164 1/20 0.50
PTPN1 P18031 2/20 0.49
BCAT2 O15382 1/20 0.47
CTSA P10619 1/20 0.47
PRKAB2 O43741 1/20 0.47
PRKAG1 P54619 1/20 0.47
PRKAA2 P54646 1/20 0.47
PRKAA1 Q13131 1/20 0.47
PRKAG3 Q9UGI9 1/20 0.47
PRKAG2 Q9UGJ0 1/20 0.47
PRKAB1 Q9Y478 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1338478 0.81 BCAT2 (0.50) ALDH1A1MAPTHSD17B10DHODHRORB
SCHEMBL982263 0.81 SMN1; SMN2 (0.54) ALDH1A1MAPTHPGDMEN1KMT2A
SCHEMBL22261532 0.80 RAB9A (0.48) ALDH1A1LMNAMAPTHSD17B10DHODH
SCHEMBL982453 0.79 ALDH1A1 (0.52) ALDH1A1MAPTHSD17B10HPGDRORB
SCHEMBL7078258 0.79 DHODH (0.54) ALDH1A1LMNAMAPTDHODHHPGD
SCHEMBL1670982 0.78 BCAT2 (0.72) ALDH1A1DHODHRORBMEN1KMT2A
SCHEMBL24508434 0.78 BCAT2 (0.50) MAPTRORBRORCMEN1KMT2A
SCHEMBL31540414 0.78 BCAT2 (0.50) ALDH1A1MAPTDHODHRORBRORC
SCHEMBL11916731 0.78 ALDH1A1 (0.49) ALDH1A1LMNAMAPTHSD17B10MEN1
SCHEMBL28253254 0.78 ALDH1A1 (0.49) ALDH1A1LMNAMAPTHSD17B10MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119977855-A Thiohydrazone method for synthesizing compound 山东金科力电源科技有限公司 2025-05-13 CN disclosed
US-8236801-B2 2-aza-bicyclo[2.2.1]heptane derivatives ACTELION PHARMACEUTICALS LTD. (CH) 2012-08-07 US disclosed
US-8236801-B2 2-aza-bicyclo[2.2.1]heptane derivatives ACTELION PHARMACEUTICALS LTD. (CH) 2012-08-07 US disclosed
US-8236801-B2 2-aza-bicyclo[2.2.1]heptane derivatives ACTELION PHARMACEUTICALS LTD. (CH) 2012-08-07 US disclosed
EP-2247586-B1 2-AZA-BICYCLO[2.2.1]HEPTANE DERIVATIVES ACTELION PHARMACEUTICALS LTD (CH) 2012-04-25 EP disclosed
US-20110009401-A1 2-AZA-BICYCLO[2.2.1]HEPTANE DERIVATIVES ACTELION PHARMACEUTICALS LTD. (CH) 2011-01-13 US disclosed
US-20110009401-A1 2-AZA-BICYCLO[2.2.1]HEPTANE DERIVATIVES ACTELION PHARMACEUTICALS LTD. (CH) 2011-01-13 US disclosed
US-20110009401-A1 2-AZA-BICYCLO[2.2.1]HEPTANE DERIVATIVES ACTELION PHARMACEUTICALS LTD. (CH) 2011-01-13 US disclosed
EP-2247586-A1 2-AZA-BICYCLO[2.2.1]HEPTANE DERIVATIVES Actelion Pharmaceuticals Ltd. (CH) 2010-11-10 EP disclosed
US-20090227629-A1 COMPOUNDS HAVING ACTIVITY AT THE GLYCINE TRANSPORTER GLYT1 AND USES THEREOF GLAXO GROUP LIMITED 2009-09-10 US disclosed
WO-2009104155-A1 2-AZA-BICYCLO[2.2.1]HEPTANE DERIVATIVES ACTELION PHARMACEUTICALS LTD (CH) 2009-08-27 WO disclosed
WO-2009104155-A1 2-AZA-BICYCLO[2.2.1]HEPTANE DERIVATIVES ACTELION PHARMACEUTICALS LTD (CH) 2009-08-27 WO disclosed
EP-2013173-A2 PYRIDINE-, ISOXAZOLE, THIOPHENECARBOXAMIDE COMPOUNDS HAVING ACTIVITY AT THE GLYCINE TRANSPORTER GLYT1 AND USES THEREOF GLAXO GROUP LIMITED (GB) 2009-01-14 EP disclosed
WO-2007080159-A2 PYRIDINE-, ISOXAZOLE, THIOPHENECARBOXAMIDE COMPOUNDS HAVING ACTIVITY AT THE GLYCINE TRANSPORTER GLYT1 AND USES THEREOF GLAXO GROUP LIMITED (GB) 2007-07-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090227629-A1 COMPOUNDS HAVING ACTIVITY AT THE GLYCINE TRANSPORTER GLYT1 AND USES THEREOF SLC18A2, SLC6A3, SLC6A2 ALDH1A1 777/4885LMNA 4479/4885MAPT 141/4885
US-20110009401-A1 2-AZA-BICYCLO[2.2.1]HEPTANE DERIVATIVES HCRTR2, HCRTR1, HCAR2 ALDH1A1 532/4885LMNA 3036/4885MAPT 3283/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.